Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
ATNM
ATNM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest ATNM ETF News Today | Earnings, Events & Price Alerts
ATNM News
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
Jan 16 2026
seekingalpha
FibroBiologics (FBLG) Stock Rises 7.68%, Attracts Market Attention
Jan 13 2026
NASDAQ.COM
Actinium Presents ATNM-400 Breast Cancer Data, Demonstrating Strong Anti-Tumor Activity
Dec 12 2025
PRnewswire
Actinium Presents New ATNM-400 Breast Cancer Data Showing Potent Efficacy
Dec 12 2025
Newsfilter
Actinium Pharmaceuticals, Inc. to Showcase ATNM-400 Findings for Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Broadening Pan-Tumor Profile Across Three Solid Tumor Types
Nov 04 2025
Newsfilter
Actinium Pharmaceuticals Unveils New Findings Showcasing Strong and Lasting Effectiveness of ATNM-400, a Pioneering Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Oct 24 2025
Newsfilter
Actinium Pharmaceuticals to Present Data on ATNM-400, a Novel Actinium-225 Radiotherapy for Multiple Tumors, in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Treatments
Oct 13 2025
Newsfilter
Actinium to Showcase ATNM-400 Preclinical Findings Demonstrating Long-lasting Tumor Control and Efficacy Against Resistance to Standard Prostate Cancer Treatments at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Oct 13 2025
Newsfilter
Actinium: Q2 Earnings Snapshot
Aug 08 2025
Yahoo Finance
HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $4 Price Target
Jun 24 2025
Benzinga
Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Jun 23 2025
Newsfilter
Life Sciences Investor Forum: Now Available for Online Viewing
Jun 13 2025
Newsfilter
Life Sciences Investor Forum Agenda Announced for June 11th-12th
Jun 10 2025
Newsfilter
Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm
Jun 10 2025
PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
May 26 2025
PRnewswire
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
May 26 2025
Globenewswire
Show More News
